Crataegus oxyacantha (Aubepine) in the use as herb medicine in France

Zhongguo Zhongyao Zazhi

Volumn 30, Issue 8, 2005, Pages 634-640

  Ju, Li Ya ^a  

^a Debiopharme S A ^*

Author keywords

C. oxyacantha

Indexed keywords

CARDIOVASCULAR AGENT; PLANT EXTRACT;

ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; CONGESTIVE HEART FAILURE; CRATAEGUS; FLOWER; FRANCE; HUMAN; ISOLATION AND PURIFICATION; MEDICINAL PLANT; PHYTOTHERAPY; REVIEW;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CRATAEGUS; FLOWERS; FRANCE; HEART FAILURE, CONGESTIVE; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 33645763027     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Ahumada C, Saenz T, Garcia D, et al. The effects of a triterpene fraction isolated from Crataegus monogyna Jacq. On different acute inflammation models in rats and mice. Leucocyte migration and phospholipese A2 inhibition. J Pharm Pharmacol, 1997, 49(3):329.
2. Bahorun T, Gresseier B, Trotin F, et al. Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparation. Arzneimittelforschung, 1996, 46(11):1086.
3. Bahorun T, Aumjaud E, Ramphul H, et al. Phenolic constituents are antioxidant capacities of Crataegus monogyna (hawthorn)callus extracts. Nahrung, 2003, 47(3):191.
4. Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung, 1995, 45(8):842.
5. Taskov M. On the coronary and cardiotonic action of crataemon. Acta Physiol Pharmacol Bulg, 1997, 3(4):53.
6. Roddwing C, Hensel H. Reaction of local myocardial blood flow in non-anesthetized dogs and anesthetized cats to the oral and parenteral administration of a Crateagus fraction (oligomere procyanidines). Arzneimittelforschung, 1997,47(7):1407.
7. VRewerski W, Piechocki T, Rylski M, et al. Einige pharmakologische eigenschaften der aus weisdom (Crataegus axyacantha) isolierten oligomeren procyanidine. Arzneim, Forsch/Drug Res, 1971, 21(6)886.
8. Stepka W, winters A D. A survey of the genus Crataegus for hypotensive activity, Lioydia, 1973, 36(4):431.
9. Roddewig C, Hensel H. Reaktion der lokalen Myokardduurchblutung von wachen hunden und narkotisierten katzen auf orale und parenterale applikation einer crataegusfraktion (oligomere procyanidine). Arzneim.-Forsch./Drug Res, 1977, 27:1407.
10. Joseph G, Zhao Y, Klaus W. Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart. Arzneimittelforschung, 1995, 45 (12):1261.
11. Schussler M, Hold J, Rump AF, et al. Functional and antiischaemic effects of monoacetyl-vitexinrhamnoside in different in vitro models. Gen Pharmacol, 1995, 26(7):1565.
12. Nasa Y, Hashizume H, Hoque AN, et al. Protective effect of crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneimittelforschung, 1993, 43(9):945.
13. Popping S, Rose H, Ionescu I, et al. Effect of a hawthom extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung, 1995, 45(11):1157.
14. Loew D. Phytogenic drugs in heart diseases exemplified by Crataegus. Wien Med Wochenschr, 1999, 149(8-10):226.
15. Shanthi S, Parasakthy K, Deepalakshmi P D, et al. Hypolipidemic activity of Crataegus in rats. Indian J Biochem Biophys, 1994, 31(2):143.
16. Rajendran S, Deepalakshmi P D, Parasakthy K, et al. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis, 1996, 123(1-2):235.
17. Quettier D C, Voiselle G, Fruchart JC, et al. Hawthorn extracts inhibit LDL oxidation. Pharmazie, 2003, 58(8):577.
18. Chatterjee S S, Koch E, Jaggy H, et al. In turn and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms. Arzneimittelforschung, 1997, 47(7):821.
19. Rakotoarison D A, Gressier B, Trotin F, et al. Anti-oxidant activities of phenolic extracts from flowers, in vitro callus and cell suspension cultures of Crataegus monogyna. Pharmazie, 1997, 52:60.
20. Shahat A A, Cos P, De Bruyne T, et al. Antiviral and antioxidant activity of flavonoids and proanthocyanidins from Crataegus sinaica. Planta Med, 2002, 68(6):539.
21. Yesilada E, Ustun O, Sezik E, et al. Inhibitory effects of turkish folk remedies on inflammatory cytokines: interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha. J Ethnopharmacol, 1997, 58:59.
22. Ammon HPT, Haendel M. Crataegus toxicology and pharmacology. Planta Med, 1981, 43(2): 105.
23. Alternative herbal health product Cactus-hawthorn compound Hyperlink http://www.herbsinfo.com/pages/cact.htm by Herbal Resources Inc.
24. Leuchtgens H. Crataegus Special Extract US 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study. Fortschr Med, 1993, 111(20-21):352.
25. Weikl A, Assnus KD, Neukum-Schmidt A, et al. Crataegus special extract US 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med, 1996, 114(24):291.
26. Bourin M, Bougerol T, Guitton B, et al. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundam Clin Pharmacol, 1997, 11(2):127.
27. Wagner H. Phytomedicine research in Germany. Environ Health Perspect, 1999, 107(10):779.
28. Schmidt U, Albrecht M, Schmidt S. Effects of an herbal Crataegus camphor combination on the symptoms of cardiovascular diseases. Arzneimittelforschung, 2000, 50(7):613.
29. Zapfe jun G. Clinical efficacy of Crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine, 2001, 8(4):262.
30. Rietbrock N, Hamel M, Hempel B, et al. Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure. Arzneimittelforschung, 2001, 51(10): 793.
31. Walker A F, Marakis G, Morris AP, et al. Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytother Res, 2002, 16(1):48.
32. Tauchert M. Efficacy and safety of crataegus extract US 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J, 2002, 143(5):910.
33. Belz G G, Butzer R, Gaus W, et al. Camphor-Crataegus berry extract combination dose-dependently reduces tilt induced fall in blood pressure in orthostatic hypotension. Phytomedicine, 2002, 9(7):581.
34. Pittler M H, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med, 2003, 114 (8):665.
35. Tankanow R, Tamer H R, Streetman D S, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus acyacantha). J Clin Pharmacol, 2003,43(6):637.
36. Degenring F H, Suter A, Weber M, et al. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patiente with congestive heart failure NYHA II. Phytomedicine, 2003, 10(5):363.
37. Hanus M, Lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin, 2004,20(1):63.
38. Pharmacopée fran.aise, X th édition, 1998.